| Total | Continuation | Discontinuation or dose reduction by adverse events | P value |
---|---|---|---|---|
Patients, n | 10 | 4 | 6 | Â |
Age (years)a | 63 (32–74) | 61 (51–64) | 65 (32–74) | 0.3329 b |
Male/Female | 5/5 | 1/3 | 4/2 | 0.5238 c |
Body weight (kg)a | 57.7 (46.0–65.8) | 58.9 (51.3–63.4) | 52.9 (46.0–65.8) | 0.4555 b |
Body surface area (m2)a | 1.57 (1.37–1.74) | 1.59 (1.47–1.70) | 1.56 (1.37–1.74) | 0.7476 b |
Body mass index (kg/m2)a | 22.1 (16.3–26.2) | 23.0 (20.9–26.2) | 21.2 (16.3–23.8) | 0.2410 b |
Aspartate aminotransferase (UI/L)a | 27 (16–43) | 29 (17–43) | 27 (16–42) | 0.6689 b |
Alanine aminotransferase (UI/L)a | 17 (12–47) | 26 (12–47) | 17 (13–42) | 1.0000 b |
Serum creatinine (mg/dL)a | 0.84 (0.61–1.47) | 0.68 (0.61–0.92) | 0.99 (0.66–1.47) | 0.0691 b |
eGFR (mL/min/1.73 m2)a | 64.9 (38.2–113.0) | 70.0 (64.5–76.0) | 50.9 (38.2–113.0) | 0.3938 b |
ECOG PS, n | ||||
0 | 6 | 2 | 4 | 0.7143 c |
1 | 3 | 2 | 1 | Â |
2 or more | 1 | 0 | 1 | Â |
Number of prior systemic therapies, n | ||||
 2 | 1 | 1 | 0 | 0.3333 c |
 3 | 7 | 2 | 5 |  |
 4 or more | 2 | 1 | 1 |  |
Initial dose, n | ||||
 10 mg/day | 8 | 2 | 6 | 0.1333c |
 7.5 mg/day | 1 | 1 | 0 |  |
 5 mg/day | 1 | 1 | 0 |  |
Everolimus blood concentration on day 8 after starting everolimus administration (ng/mL)a | 15.3 (8.1–28.0) | 8.2 (8.1–9.8) | 18.0 (13.7–28.0) | 0.0139b |
Everolimus blood concentration just before discontinuation or dose reduction (ng/mL)a | 14.8 (6.4–58.4) | 9.7 (6.4–17.1) | 22.9 (12.5–58.4) | 0.0142b |
Change of everolimus blood concentration just before discontinuation or dose reduction from day 8 (absolute value, ng/mL)a | 1.65 (0.03–36.60) | 2.00 (0.03–8.90) | 1.40 (0.20–36.60) | 0.3374b |